| Methylprednisolone |
II-9509/10.08.2004 |
SOLU-MEDROL, Powder and solvent for solution for injection, 125, mg, Pack: 1 |
Pfizer Enterprises SARL, Люксембург |
Pfizer Manufacturing Belgium N.V./S.A., Rijksweg 12 B-2870, Puurs, Belgium |
3.29 |
0.66 |
3.95 |
7% |
0.23 |
3.52 |
0.7 |
4.22 |
20% |
0.66 |
4.18 |
0.84 |
5.02 |
|
КЦ-672/06.03.2009 |
23.03.2009 |
23.03.2009 |
Неактивен |
1639 |
| Somatostatin |
II-14278/27.09.2006 |
SOMATOSTATIN LYOMARK, Powder for solution for injection/infusion, 3, mg, Pack: 5 |
Lyomark Pharma GmbH, Германия |
Wasserburger Arzneimittelwerk GmbH, Germany |
567.19 |
113.44 |
680.63 |
4% |
10 |
577.19 |
115.44 |
692.63 |
16% |
25 |
602.19 |
120.44 |
722.63 |
Протокол №242/14.09.2017 |
КЦ-1152/07.10.2009 |
29.10.2009 |
02.10.2017 |
Активен |
832 |
| Somatostatin |
II-14278/27.09.2006 |
SOMATOSTATIN LYOMARK, Powder and solvent for solution for injection, 3, mg, Pack: 1 |
Lyomark Pharma GmbH, Германия |
Wasserburger Arzneimittelwerk GmbH, Germany |
131.04 |
26.21 |
157.25 |
4% |
5.24 |
136.28 |
27.26 |
163.54 |
16% |
20.97 |
157.25 |
31.45 |
188.7 |
Прот. № 217/30.03.2017 |
КЦ-1152/07.10.2009 |
29.10.2009 |
02.04.2017 |
Активен |
831 |
| Somatostatin |
II-14278/27.09.2006 |
SOMATOSTATIN LYOMARK 3, Powder and solvent for solution for injection, 3, mg, Pack: 5 |
Lyomark Pharma GmbH, Германия |
Wasserburger Arzneimittelwerk GmbH, Germany |
567.19 |
113.44 |
680.63 |
4% |
10 |
577.19 |
115.44 |
692.63 |
16% |
25 |
602.19 |
120.44 |
722.63 |
|
КЦ-1152/07.10.2009 |
29.10.2009 |
29.10.2009 |
Неактивен |
832 |
| Somatostatin |
II-14278/27.09.2006 |
SOMATOSTATIN LYOMARK 3, Powder and solvent for solution for injection, 3, mg, Pack: 1 |
Lyomark Pharma GmbH, Германия |
Wasserburger Arzneimittelwerk GmbH, Germany |
131.04 |
26.21 |
157.25 |
4% |
5.24 |
136.28 |
27.26 |
163.54 |
16% |
20.97 |
157.25 |
31.45 |
188.7 |
|
КЦ-1152/07.10.2009 |
29.10.2009 |
29.10.2009 |
Неактивен |
831 |
| Somatostatin |
20120385 |
Somatostatin PH&T, Powder and solvent for solution for injection, 3, mg, Pack: 1 флакон + 1 ампула |
PH & T S.p.A., Италия |
Alfa Wassermann S.p.A., Италия |
93.96 |
18.79 |
112.75 |
4% |
3.76 |
97.72 |
19.54 |
117.26 |
16% |
15.03 |
112.75 |
22.55 |
135.3 |
|
НСР-4635/15.09.2014; НСР-13233/17.07.2017 |
30.09.2014 |
02.09.2017 |
Заличен |
3172 |
| Somatostatin |
20120385 |
Somatostatin PH&T, Powder and solvent for solution for injection, 3, mg, Pack: 1 флакон + 1 ампула |
PH & T S.p.A., Италия |
Alfa Wassermann S.p.A., Италия |
93.96 |
18.79 |
112.75 |
4% |
3.76 |
97.72 |
19.54 |
117.26 |
16% |
15.03 |
112.75 |
22.55 |
135.3 |
|
НСР-4635/15.09.2014 |
30.09.2014 |
30.09.2014 |
Неактивен |
3172 |
| Somatostatin |
II-0860/15.10.2007 |
Somatostatin-UCB, Powder and solvent for solution for infusion, 3, mg, Pack: 1 |
UCB Pharma SA, Белгия |
UCB Pharma SA, Belgium |
44.53 |
8.91 |
53.44 |
4% |
1.78 |
46.31 |
9.26 |
55.57 |
16% |
7.12 |
53.43 |
10.69 |
64.12 |
|
КЦРР-1205/13.08.2012 г;; НСР-12049/21.03.2017 |
28.12.2012 |
02.05.2017 |
Заличен |
1498 |
| Somatostatin |
II-0860/15.10.2007 |
Somatostatin-UCB, Powder and solvent for solution for infusion, 3, mg, Pack: 1 |
UCB Pharma SA, Белгия |
UCB Pharma SA, Belgium |
44.53 |
8.91 |
53.44 |
4% |
1.78 |
46.31 |
9.26 |
55.57 |
16% |
7.12 |
53.43 |
10.69 |
64.12 |
|
КЦРР-1205/13.08.2012 г |
28.12.2012 |
28.12.2012 |
Неактивен |
1498 |
| Somatostatin |
II-0859/15.10.2007 |
Somatostatin-UCB, Powder and solvent for solution for infusion, 0.25, mg, Pack: 1 |
UCB Pharma SA, Белгия |
UCB Pharma SA, Belgium |
3.72 |
0.74 |
4.46 |
7% |
0.26 |
3.98 |
0.8 |
4.78 |
20% |
0.74 |
4.72 |
0.94 |
5.66 |
|
НСР-5738/26.02.2015.; НСР-12049/21.03.2017 |
12.03.2015 |
02.05.2017 |
Заличен |
3635 |
| Somatostatin |
II-0859/15.10.2007 |
Somatostatin-UCB, Powder and solvent for solution for infusion, 0.25, mg, Pack: 1 |
UCB Pharma SA, Белгия |
UCB Pharma SA, Belgium |
3.72 |
0.74 |
4.46 |
7% |
0.26 |
3.98 |
0.8 |
4.78 |
20% |
0.74 |
4.72 |
0.94 |
5.66 |
|
НСР-5738/26.02.2015. |
12.03.2015 |
12.03.2015 |
Неактивен |
3635 |
| Somatostatin |
II-0859/15.10.2007 |
Somatostatin-UCB, Powder and solvent for solution for infusion, 0.25, mg, Pack: 1 |
UCB Pharma SA, Белгия |
UCB Pharma SA, Belgium |
3.91 |
0.78 |
4.69 |
7% |
0.27 |
4.18 |
0.84 |
5.02 |
20% |
0.78 |
4.96 |
0.99 |
5.95 |
|
КЦРР-1205/13.08.2012 г |
28.12.2012 |
28.12.2012 |
Неактивен |
3635 |
| Somatostatin |
II-0860/15.10.2007 |
Somatostatin-UCB, Powder and solvent for solution for infusion, 3, mg, Pack: 1 |
UCB Pharma SA, Белгия |
UCB Pharma SA, Belgium |
89.58 |
17.92 |
107.5 |
4% |
3.58 |
93.16 |
18.63 |
111.79 |
16% |
14.33 |
107.49 |
21.5 |
128.99 |
|
КЦ-673/06.03.2009 |
24.03.2009 |
24.03.2009 |
Неактивен |
1498 |
| Somatostatin |
II-0859/15.10.2007 |
Somatostatin-UCB, Powder and solvent for solution for infusion, 0.25, mg, Pack: 1 |
UCB Pharma SA, Белгия |
UCB Pharma SA, Belgium |
18.66 |
3.73 |
22.39 |
6% |
1.12 |
19.78 |
3.96 |
23.74 |
18% |
3.36 |
23.14 |
4.63 |
27.77 |
|
КЦ-673/06.03.2009 |
24.03.2009 |
24.03.2009 |
Неактивен |
3635 |
| Pegvisomant |
EU/1/02/240/001 |
Somavert, Powder and solvent for solution for injection, 10, mg, Pack: 30 vials + 30 pre -filled syringes |
Pfizer Europe MA EEIG, Белгия |
Pfizer Manufacturing Belgium NV, Belgium |
3238.78 |
647.76 |
3886.54 |
4% |
10 |
3248.78 |
649.76 |
3898.54 |
16% |
25 |
3273.78 |
654.76 |
3928.54 |
Протокол №242/14.09.2017; Промяна на обстоятелствата НСР-17199/09.11.2018 |
НСР-8981/14.04.2016.; НСР-17510/13.12.2018 |
28.12.2018 |
02.01.2019 |
Активен |
3300 |
| Pegvisomant |
EU/1/02/240/001 |
Somavert, Powder and solvent for solution for injection, 10, mg, Pack: 30 vials + 30 pre -filled syringes |
Pfizer Europe MA EEIG, Белгия |
Pfizer Manufacturing Belgium NV, Belgium |
3251.12 |
650.22 |
3901.34 |
4% |
10 |
3261.12 |
652.22 |
3913.34 |
16% |
25 |
3286.12 |
657.22 |
3943.34 |
Протокол №242/14.09.2017; Промяна на обстоятелствата НСР-17199/09.11.2018 |
НСР-8981/14.04.2016. |
30.04.2016 |
02.12.2018 |
Неактивен |
3300 |
| Pegvisomant |
EU/1/02/240/001 |
Somavert, Powder and solvent for solution for injection, 10, mg, Pack: 30 vials + 30 pre -filled syringes |
Pfizer Limited, Обединено Кралство |
Pfizer Manufacturing Belgium NV, Belgium |
3251.12 |
650.22 |
3901.34 |
4% |
10 |
3261.12 |
652.22 |
3913.34 |
16% |
25 |
3286.12 |
657.22 |
3943.34 |
Протокол №242/14.09.2017 |
НСР-8981/14.04.2016. |
30.04.2016 |
02.10.2017 |
Неактивен |
3300 |
| Pegvisomant |
EU/1/02/240/002 |
Somavert, Powder and solvent for solution for injection, 15, mg, Pack: 30 vials + 30 pre -filled syringes |
Pfizer Europe MA EEIG, Белгия |
Pfizer Manufacturing Belgium NV, Belgium |
4834.36 |
966.87 |
5801.23 |
4% |
10 |
4844.36 |
968.87 |
5813.23 |
16% |
25 |
4869.36 |
973.87 |
5843.23 |
Протокол №242/14.09.2017; Промяна на обстоятелствата НСР-17199/09.11.2018 |
НСР-8982/14.04.2016.; НСР-16011/25.06.2018 с предварително изпълнение |
25.06.2018 |
02.12.2018 |
Активен |
3301 |
| Pegvisomant |
EU/1/02/240/002 |
Somavert, Powder and solvent for solution for injection, 15, mg, Pack: 30 vials + 30 pre -filled syringes |
Pfizer Limited, Обединено Кралство |
Pfizer Manufacturing Belgium NV, Belgium |
4834.36 |
966.87 |
5801.23 |
4% |
10 |
4844.36 |
968.87 |
5813.23 |
16% |
25 |
4869.36 |
973.87 |
5843.23 |
Протокол №242/14.09.2017 |
НСР-8982/14.04.2016.; НСР-16011/25.06.2018 с предварително изпълнение |
25.06.2018 |
02.08.2018 |
Неактивен |
3301 |
| Pegvisomant |
EU/1/02/240/002 |
Somavert, Powder and solvent for solution for injection, 15, mg, Pack: 30 vials + 30 pre -filled syringes |
Pfizer Limited, Обединено Кралство |
Pfizer Manufacturing Belgium NV, Belgium |
4834.36 |
966.87 |
5801.23 |
4% |
10 |
4844.36 |
968.87 |
5813.23 |
16% |
25 |
4869.36 |
973.87 |
5843.23 |
Протокол №242/14.09.2017 |
НСР-8982/14.04.2016.; НСР-16011/25.06.2018 с предварително изпълнение* |
25.06.2018 |
02.07.2018 |
Неактивен |
3301 |
| Pegvisomant |
EU/1/02/240/002 |
Somavert, Powder and solvent for solution for injection, 15, mg, Pack: 30 vials + 30 pre -filled syringes |
Pfizer Limited, Обединено Кралство |
Pfizer Manufacturing Belgium NV, Belgium |
4880.58 |
976.12 |
5856.7 |
4% |
10 |
4890.58 |
978.12 |
5868.7 |
16% |
25 |
4915.58 |
983.12 |
5898.7 |
Протокол №242/14.09.2017 |
НСР-8982/14.04.2016. |
30.04.2016 |
02.10.2017 |
Неактивен |
3301 |
| Pegvisomant |
EU/1/02/240/003 |
Somavert, Powder for solution for injection, 20, mg, Pack: 30 |
Pfizer Limited, Обединено Кралство |
Pfizer Manufacturing Belgium NV, Belgium |
6919.96 |
1383.99 |
8303.95 |
4% |
10 |
6929.96 |
1385.99 |
8315.95 |
16% |
25 |
6954.96 |
1390.99 |
8345.95 |
цената се заличава КЦРР-2538/14.03.2013 |
КЦ-3163/04.11.2011 |
06.03.2013 |
06.03.2013 |
Заличен |
1643 |
| Pegvisomant |
EU/1/02/240/003 |
Somavert, Powder for solution for injection, 20, mg, Pack: 30 |
Pfizer Limited, Обединено Кралство |
Pfizer Manufacturing Belgium NV, Belgium |
7132.23 |
1426.45 |
8558.68 |
4% |
10 |
7142.23 |
1428.45 |
8570.68 |
16% |
25 |
7167.23 |
1433.45 |
8600.68 |
изготвено корекционно решение КЦ-670/06.03.2009 |
КЦ-575/23.02.2009 |
10.03.2009 |
10.03.2009 |
Неактивен |
1643 |
| Pegvisomant |
EU/1/02/240/002 |
Somavert, Powder and solvent for solution for injection, 15, mg, Pack: 15 mg powder x 30 vials + 8 ml solvent x 30 vials |
Pfizer Limited, Обединено Кралство |
Pfizer Manufacturing Belgium NV, Belgium |
4880.58 |
976.12 |
5856.7 |
4% |
10 |
4890.58 |
978.12 |
5868.7 |
16% |
25 |
4915.58 |
983.12 |
5898.7 |
|
НСР-8982/14.04.2016. |
30.04.2016 |
30.04.2016 |
Неактивен |
3301 |
| Pegvisomant |
EU/1/02/240/002 |
Somavert, Powder and solvent for solution for injection, 15, mg, Pack: 15 mg powder x 30 vials + 8 ml solvent x 30 vials |
Pfizer Limited, Обединено Кралство |
Pfizer Manufacturing Belgium NV, Belgium |
4902.09 |
980.42 |
5882.51 |
4% |
10 |
4912.09 |
982.42 |
5894.51 |
16% |
25 |
4937.09 |
987.42 |
5924.51 |
Прот. № 136/16.09.2015 |
НСР-6850/30.07.2015 |
14.08.2015 |
14.08.2015 |
Неактивен |
3301 |